NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
Clinical Trials
21 trialsNCT07189793 2025-09-24
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT04887831 2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT06632951 2025-08-11
LIVIGNO-3
AbbVie
Phase 2 Active not recruiting
NCT01261728 2025-08-08
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT07043972 2025-07-20
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Recruiting
NCT03093922 2025-04-22
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02887248 2023-12-05
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT01524991 2022-07-11
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Completed
NCT03520231 2021-11-23
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
Phase 2 Completed
NCT05030077 2021-09-01
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03051373 2021-08-09
Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
Chinese PLA General Hospital
Phase 2 Completed
NCT02665039 2019-10-08
VINGEM
Karolinska University Hospital
Phase 2 Completed
NCT01828736 2017-02-06
CVH-CT02
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT00588666 2016-01-22
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01599013 2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2 Completed
NCT00696007 2012-02-17
Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
Lahey Clinic
Phase 2 Withdrawn
NCT00191971 2007-11-06
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
Eli Lilly and Company
Phase 2 Completed
NCT00173862 2007-07-25
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
National Taiwan University Hospital
Phase 2 Completed